Literature DB >> 27481953

The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public-Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia.

Bruno François1, Jean Chastre2, Philippe Eggiman3, Pierre-François Laterre4, Antoni Torres5, Miguel Sanchez6, Mark T Esser7, Brian Bishop7, Marc Bonten8, Herman Goosens9, Hasan S Jafri7.   

Abstract

The Innovative Medicines Initiative-funded COMBACTE consortium fosters academic-industry partnership in pioneering studies to combat serious bacterial infections. We describe how this partnership is advancing the development of 2 monoclonal antibodies, MEDI4893 and MEDI3902, for the prevention of nosocomial pneumonia.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  ICU; monoclonal antibody; nosocomial pneumonia; ventilator-associated pneumonia

Mesh：

Substances：

Year:  2016        PMID： 27481953     DOI： 10.1093/cid/ciw245

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  7 in total

1.  Treatment of severe MRSA infections: current practice and further development.

Authors:  José-Artur Paiva; Philippe Eggimann
Journal:  Intensive Care Med       Date:  2016-10-04       Impact factor: 17.440

Review 2.  The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship.

Authors:  Marin H Kollef; Matteo Bassetti; Bruno Francois; Jason Burnham; George Dimopoulos; Jose Garnacho-Montero; Jeffrey Lipman; Charles-Edouard Luyt; David P Nicolau; Maarten J Postma; Antonio Torres; Tobias Welte; Richard G Wunderink
Journal:  Intensive Care Med       Date:  2017-02-04       Impact factor: 17.440

3.  Prevalence of IgG and Neutralizing Antibodies against Staphylococcus aureus Alpha-Toxin in Healthy Human Subjects and Diverse Patient Populations.

Authors:  Yuling Wu; Xu Liu; Ahmad Akhgar; Jia J Li; Hoyin Mok; Bret R Sellman; Li Yu; Lorin K Roskos; Mark T Esser; Alexey Ruzin
Journal:  Infect Immun       Date:  2018-02-20       Impact factor: 3.441

Review 4.  The making of bispecific antibodies.

Authors:  Ulrich Brinkmann; Roland E Kontermann
Journal:  MAbs       Date:  2017 Feb/Mar       Impact factor: 5.857

5.  Rationale and design of ASPIRE-ICU: a prospective cohort study on the incidence and predictors of Staphylococcus aureus and Pseudomonas aeruginosa pneumonia in the ICU.

Authors:  Fleur P Paling; Darren P R Troeman; Martin Wolkewitz; Rubana Kalyani; Daniël R Prins; Susanne Weber; Christine Lammens; Leen Timbermont; Herman Goossens; Surbhi Malhotra-Kumar; Frangiscos Sifakis; Marc J M Bonten; Jan A J W Kluytmans
Journal:  BMC Infect Dis       Date:  2017-09-25       Impact factor: 3.090

Review 6.  The Innovative Medicines Initiative -10 Years of Public-Private Collaboration.

Authors:  Hugh Laverty; Pierre Meulien
Journal:  Front Med (Lausanne)       Date:  2019-12-03

Review 7.  [Update of the recommendations of the Pneumonia Zero project].

Authors:  S Arias-Rivera; R Jam-Gatell; X Nuvials-Casals; M Vázquez-Calatayud
Journal:  Enferm Intensiva       Date:  2022-07-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.